Indian pharma major Dr. Reddy’s said that its manufacturing plant in Bachupally, Hyderabad was inspected by the United States Food & Drug Administration (US FDA) from October 19, 2023, to October 27, 2023.
As a result, the plant received a Form 483 with ten observations. The inspection was a routine cGMP inspection at the company's formulations manufacturing facility (FTO-3) in Hyderabad. Dr. Reddy's stated that it will address the observations within the stipulated timeline.
Follow our LIVE blog for all the market action & business updates
Dr. Reddy's announced on October 27 that it achieved its highest-ever consolidated net profit of Rs 1,480 crore in the July-September quarter, which is a 33 percent increase from the same period last year when it reported a profit of Rs 1,112.80 crore.
In the second quarter, the company's North America business generated a revenue of Rs. 3170 crore, showing a YoY growth of 13 percent, although it experienced a QoQ decline of 1 percent. The growth was due to a rise in momentum in its core portfolio, Mayne integration, favorable foreign exchange, which was partially offset by price erosion.
As of 10:02 am, shares of the company are trading down 1.64 percent on NSE at Rs. 5,308.80.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
